ISL
BMRN icon

Ingalls & Snyder LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ingalls & Snyder LLC’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,380
Closed -$616K – 458
2021
Q2 		$616K Sell
7,380
-1,735
-19% -$138K 0.03% 291
2021
Q1 		$688K Sell
9,115
-1,560
-15% -$127K 0.03% 260
2020
Q4 		$936K Sell
10,675
-165
-2% -$13.1K 0.05% 230
2020
Q3 		$825K Buy
+10,840
New +$1.1M 0.06% 194

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ingalls & Snyder LLC's BMRN Position: Q3 2021 in Review

Ingalls & Snyder LLC sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 7,380 shares — an estimated $616K sold.

Ingalls & Snyder LLC first reported a position in BMRN in Q3 2020 and held it in 4 quarters. The position peaked at $936K in Q4 2020. 511 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

  • Ingalls & Snyder LLC reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 7,380 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $616K.
  • Ingalls & Snyder LLC first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Ingalls & Snyder LLC's BioMarin Pharmaceuticals position peaked at $936K in Q4 2020.
  • 511 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Ingalls & Snyder LLC's 13F filing for Q3 2021, filed 27 Oct 2021.